Actinium Pharmaceuticals Issues Mid-Year Letter to Shareholders Highlighting Accomplishments and Significant Value Enumerating Catalysts Over the Coming Quarters
15 juin 2017 08h30 HE
|
Actinium Pharmaceuticals
- Iomab-B Phase 3 SIERRA trial enrollment is accelerating as the number of clinical trial sites increase, competitive position as only induction and conditioning regimen remains unchallenged -...
Actinium Pharmaceuticals Announces Appointment of Nitya Ray, Ph.D. as Executive Vice-President, Head of Product Development, Manufacturing and Supply Chain and Other Key Hires in its Product Development and Manufacturing Teams
15 juin 2017 07h00 HE
|
Actinium Pharmaceuticals
- Dr. Nitya Ray joins Actinium Executive Team with 30 years of radiopharmaceutical and biologics product development, manufacturing and strategic planning experience - Also announced is the recent...
Actinium Pharmaceuticals to Host Webinar on June 12th to Update on Pivotal Phase 3 SIERRA Clinical Trial for Iomab-B
12 juin 2017 07h00 HE
|
Actinium Pharmaceuticals
Dr. Rajneesh Nath, a Principal Investigator and Director of the Bone Marrow Transplant and Acute Leukemia Program at Banner MD Anderson Cancer Center will discuss his perspectives on Iomab-B in...
Actinium Pharmaceuticals Announces Appointment of Sandesh Seth as Chief Executive Officer
09 juin 2017 07h30 HE
|
Actinium Pharmaceuticals
- Mr. Seth to serve as Chief Executive Officer and Chairman of the Board of Directors - Independent Director Dr. Ajit Shetty appointed to the Company’s Corporate Governance, Audit and Compensation...
Actinium Pharmaceuticals Highlights Presence at Upcoming Society of Nuclear Medicine and Molecular Imaging Annual Meeting
08 juin 2017 07h30 HE
|
Actinium Pharmaceuticals
- Society of Nuclear Medicine and Molecular Imaging to be held June 10 – 14, 2017 in Denver, Colorado - Actinium to conduct webinar to provide an update on its Pivotal Phase 3 drug...
UPDATE – Actinium Pharmaceuticals to Host Webinar on June 12th to Update on Pivotal Phase 3 SIERRA Clinical Trial for Iomab-B
08 juin 2017 07h00 HE
|
Actinium Pharmaceuticals
- Dr. Rajneesh Nath, a Principal Investigator and Director of the Bone Marrow Transplant and Acute Leukemia Program at Banner MD Anderson Cancer Center will discuss his perspectives on Iomab-B in...
Actinium Pharmaceuticals to Host Webinar on June 12th to Update on Pivotal Phase 3 SIERRA Clinical Trial for Iomab-B
31 mai 2017 07h30 HE
|
Actinium Pharmaceuticals
- Dr. Rajneesh Nath, a Principal Investigator and Director of the Bone Marrow Transplant and Acute Leukemia Program at Banner MD Anderson Cancer Center will discuss his perspectives on Iomab-B in...
Actinium Pharmaceuticals Granted Orphan Designation from the European Medicines Agency for Actimab-A
24 mai 2017 09h22 HE
|
Actinium Pharmaceuticals
- Orphan designation provides increased communication and guidance from regulators and 10-year market exclusivity upon marketing authorization- Actinium’s two leading drug candidates, Iomab-B and...
Actinium Pharmaceuticals to Present Actimab-A Data at the 10th International Symposium on Targeted Alpha Therapy
23 mai 2017 07h30 HE
|
Actinium Pharmaceuticals
- Data from the Company’s Actimab-A program to be presented in the Clinical Experiences session being held on Wednesday, May 31, 2017 - Actinium is a sponsor of the conference...
Actinium Pharmaceuticals Announces Appointment of Hematology Expert Dr. Richard Stone of the Dana-Farber Cancer Institute to its Scientific Advisory Board
17 mai 2017 07h00 HE
|
Actinium Pharmaceuticals
Dr. Stone is a world renowned physician with extensive research and clinical experience focused on refractory leukemia patients and advanced myeloproliferative disordersActinium’s Scientific Advisory...